TRAF6-Dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation

Molecular and Cellular Biology

Volumn 32, Issue 19, 2012, Pages 3925-3937

  Qu, Fangfang ^a   Gao, Hanchao ^a   Zhu, Shu ^a   Shi, Peiqing ^a   Zhang, Yifan ^a   Liu, Yan ^a   Jallal, Bahija ^b   Yao, Yihong ^b   Shi, Yufang ^a   Qian, Youcun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACT1 PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; PHOSPHOTRANSFERASE; RECOMBINANT PROTEIN; TANK BINDING KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CONNEXIN 43; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-17; MICE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, INTERLEUKIN-17; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84868704128     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00268-12     Document Type: Article

References (40)

1. Bulek K, et al. 2011. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat. Immunol. 12:844-852.
2. Chang SH, Dong C. 2009. IL-17F: regulation, signaling and function in inflammation. Cytokine 46:7-11.
3. Chang SH, Park H, Dong C. 2006. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 281:35603-35607.
4. Chen ZJ. 2005. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7:758 -765.
5. Clément JF, Meloche S, Servant MJ. 2008. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 18:889-899.
6. Cua DJ, Tato CM. 2010. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10:479-489.
7. Gaffen SL. 2011. Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23:613- 619.
8. Gaffen SL. 2009. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9:556 -567.
9. Häcker H, Karin M. 2006. Regulation and function of IKK and IKKrelated kinases. Sci. STKE 2006:re13.
10. Hacker H, et al. 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439:204 -207.
11. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. 2007. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179:4135- 4141.
12. Hartupee J, et al. 2009. IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J. Immunol. 182:1660 -1666.
13. Hemmi H, et al. 2004. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199:1641-1650.
14. Ho AW, et al. 2010. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. 185:1063-1070.
15. Ishii KJ, et al. 2008. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451:725-729.
16. Iwakura Y, Ishigame H, Saijo S, Nakae S. 2011. Functional specialization of interleukin-17 family members. Immunity 34:149 -162.
17. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373- 384.
18. Kishore N, et al. 2002. IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2. J. Biol. Chem. 277:13840 -13847.
19. Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27:485-517.
20. Leonardi A, Chariot A, Claudio E, Cunningham K, Siebenlist U. 2000. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 97:10494 -10499.
21. Li X, et al. 2000. Act1, an NF-kappa B-activating protein. Proc. Natl. Acad. Sci. U. S. A. 97:10489 -10493.
22. Liu C, et al. 2009. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci. Signal. 2:ra63.
23. McAleer JP, Kolls JK. 2011. Mechanisms controlling Th17 cytokine expression and host defense. J. Leukoc. Biol. 90:263-270.
24. Oganesyan G, et al. 2006. Critical role of TRAF3 in the Toll-like receptordependent and -independent antiviral response. Nature 439:208 -211.
25. Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G. 2004. Differential requirement for TANK-binding kinase-1 in type I interferon responses to Toll-like receptor activation and viral infection. J. Exp. Med. 199:1651-1658.
26. Qian Y, Kang Z, Liu C, Li X. 2010. IL-17 signaling in host defense and inflammatory diseases. Cell. Mol. Immunol. 7:328 -333.
27. Qian Y, et al. 2007. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8:247-256.
28. Schwandner R, Yamaguchi K, Cao Z. 2000. Requirement of tumor necrosis factor receptor-associated factor (Traf)6 in interleukin 17 signal transduction. J. Exp. Med. 191:1233-1240.
29. Shen F, et al. 2009. IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci. Signal. 2:ra8.
30. Shen RR, Hahn WC. 2011. Emerging roles for the non-canonical IKKs in cancer. Oncogene 30:631- 641.
31. Shi P, et al. 2011. Persistent stimulation with interleukin-17 desensitizes cells through SCFbeta-TrCP-mediated degradation of Act1. Sci. Signal. 4:ra73.
32. Sønder SU, et al. 2011. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J. Biol. Chem. 286:12881-12890.
33. Song X, et al. 2011. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12:1151-1158.
34. Sun D, et al. 2011. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 12:853- 860.
35. Tenoever BR, et al. 2007. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315: 1274-1278.
36. Thurston TL, Ryzhakov G, Bloor S, von Muhlinen N, Randow F. 2009. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat. Immunol. 10:1215-1221.
37. Zepp JA, et al. 2012. Cutting edge: TNF receptor-associated factor 4 restricts IL-17-mediated pathology and signaling processes. J. Immunol. 189:33-37.
38. Zhu S, et al. 2010. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J. Exp. Med. 207:2647-2662.
39. Zhu S, et al. 2012. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat. Med. 18:1077-1086.
40. Zhu S, Qian Y. 2012. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin. Sci. (Lond.) 122:487-511.